BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Should You Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped down before the market opened on Tuesday . The stock had previously closed at $9.96, but opened at $9.12. BioCryst Pharmaceuticals shares last traded at $9.0320, with a volume of 1,651,086 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BCRX shares. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Thursday, August 27th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Royal Bank Of Canada reduced their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Trading Down 2.8%

The business’s 50 day simple moving average is $9.72 and its two-hundred day simple moving average is $9.23. The firm has a market capitalization of $2.25 billion, a PE ratio of -5.87 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.15 earnings per share. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Bank of America Corp DE grew its stake in BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after acquiring an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. bought a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $14,880,000. Wedge Capital Management L L P NC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth $3,808,000. Rice Hall James & Associates LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth $23,320,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at about $1,330,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.